Last reviewed · How we verify

Curare (Atracurium) — Competitive Intelligence Brief

Curare (Atracurium) (Curare (Atracurium)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesia.

marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor (neuromuscular junction) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Curare (Atracurium) (Curare (Atracurium)) — CHU de Reims. Atracurium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, causing paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Curare (Atracurium) TARGET Curare (Atracurium) CHU de Reims marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor (neuromuscular junction)
sufficient dose of rocuronium sufficient dose of rocuronium Korea University Guro Hospital marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
NMBA - cisatracurium NMBA - cisatracurium CHU de Reims marketed Non-depolarizing neuromuscular blocking agent (NMBA) Nicotinic acetylcholine receptor at the neuromuscular junction
Muscle Relaxant (Rocuronium) Muscle Relaxant (Rocuronium) Ostfold Hospital Trust marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor (neuromuscular junction)
Atracurium, TBW Atracurium, TBW St. Antonius Hospital marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
NIMBEX NIMBEX Assistance Publique Hopitaux De Marseille marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
Rocuronium Injectable Solution Rocuronium Injectable Solution Federal University of São Paulo marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

  1. University Hospital, Antwerp · 3 drugs in this class
  2. Ain Shams University · 2 drugs in this class
  3. Merck Sharp & Dohme LLC · 2 drugs in this class
  4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
  5. Federal University of São Paulo · 1 drug in this class
  6. Korea University Guro Hospital · 1 drug in this class
  7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  8. Ostfold Hospital Trust · 1 drug in this class
  9. St. Antonius Hospital · 1 drug in this class
  10. CHU de Reims · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Curare (Atracurium) — Competitive Intelligence Brief. https://druglandscape.com/ci/curare-atracurium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: